More than 20 years of experience in immunology and oncology research and drug discovery President of Cytimm Therapeutics. Leading the overall strategy of the company and pipeline development, especially in the field of Immuno-Oncology, autoimmune diseases and neurodegenerative diseases. Dr. Huang initiated and developed the Immuno-Oncology pipeline as the Vice President of drug discovery in ACEA therapeutics. In Feb 2020, he led the spinning-off of the division from ACEA and co-founded Cytimm Therapeutics. Before joining ACEA, Haining was the senior director of immuno-oncology at Oxford Biotherapeutics, where he led the drug discovery process from target identification to preclinical development. During his time at Oxford Biotherapeutics, he strengthened the corporate pipeline, supported the generation of key IPs, and led data package preparation for investigational new drug (IND) filings. Prior to that, Haining was a group leader at Sorrento Therapeutics, responsible for the preclinical R&D of CAR-T immunotherapy. Dr. Huang get his Ph.D degree in Fudan University in Molecular Immunology.